MARLBOROUGH, Mass.,
Oct. 12, 2015 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
biotechnology company focused on discovering and developing
innovative therapies primarily in the areas of dermatology and
ophthalmology, today announced that Dr. Robert Galiano, one of the Company's Principal
Investigators for the RXI-109 clinical program, will present during
The Plastic Surgery Foundation (PSF) Industry Summit. The
Summit will take place on Sunday, October
18, 2015 from 3:30-4:45 p.m.
EDT in Boston,
Massachusetts. Dr. Galiano will present an overview of the
Company's dermal clinical program with RXI-109. The presentation
will be available on the "Investors" section of the Company's
website, www.rxipharma.com.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Dr. Robert Galiano is an
Associate Professor and Director of Research in the Division of
Plastic Surgery at Northwestern
University Feinberg School of Medicine and a plastic surgeon
at Northwestern Memorial Hospital. He is a Board-Certified
Plastic Surgeon who is actively involved in several scar-related
basic and clinical research studies. He is the Principal
Investigator in clinical trials investigating the efficacy of
various scar treatments, including RXI-109, as well as studies
assessing the quality of scar evaluation methods. In
addition, Dr. Galiano assisted in the development of the
Northwestern University human
abdominoplasty in vivo scar model, a novel research model to
assess the efficacy of scar therapeutics.
The PSF Industry Summit provides a venue to gather real-time
data and market research from ~ 60 respected American Society
of Plastic Surgeon including leaders, symposia faculty, committee
chairs, and investment advisors. This event will connect
innovators, companies and key opinion leaders (KOLs) in
plastic surgery to gain valuable feedback.
The PSF takes place during, 'Plastic Surgery: The Meeting 2015'.
Now in its 89th year and with more than 3,000
attendees, this conference is the world's largest gathering of
plastic surgeons and surgical medical professionals who are
interested in bringing the most leading-edge clinical information
to their practice, to enhance patient satisfaction and surgical
outcomes.
About the Plastic Surgery Foundation
The American Society of Plastic Surgeons (ASPS) works in concert
with The Plastic Surgery Foundation. Founded in 1948, The
PSF's mission is to improve the quality of patient care through
research and development. The Foundation supports research through
a variety of grants, clinical trials networks, training programs
and forums that encourage innovation in medical devices and
techniques.
About ASPS
ASPS is the world's largest organization of board-certified
plastic surgeons. Representing more than 7,000 Member
Surgeons, the Society is recognized as a leading authority and
information source on aesthetic and reconstructive plastic surgery.
The ASPS comprises more than 94 percent of all board-certified
plastic surgeons in the United
States. Founded in 1931, the Society represents physicians
certified by either The American Board of Plastic Surgery or The
Royal College of Physicians and Surgeons of Canada. The ASPS advances quality care
to plastic surgery patients by encouraging high standards of
training, ethics, physician practice and research in plastic
surgery.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering and developing
innovative therapeutics primarily in the areas of dermatology and
ophthalmology that address high-unmet medical needs. Our discovery
and clinical development programs are based on siRNA technology as
well as immunotherapy agents. These compounds include, but are not
limited to, our proprietary, self-delivering RNAi (sd-rxRNA®)
compounds for the treatment of dermal and ocular scarring. It also
includes an immunomodulator, Samcyprone™, a proprietary topical
formulation of diphenylcyclopropenone (DPCP), for the treatment of
disorders such as warts, alopecia areata, non-malignant skin tumors
and cutaneous metastases of melanoma.
RXi's novel, self-delivering RNAi (sd-rxRNA®) compounds are
designed for therapeutic use and have drug-like properties, such as
high potency, target specificity, serum stability, reduced immune
response activation, and efficient cellular uptake. sd-rxRNAs have
been shown, in vitro and in vivo, to achieve
efficient spontaneous cellular uptake and potent, long-lasting
intracellular activity.
Building on the pioneering work of RXi's Scientific Advisory
Board Chairman and Nobel Laureate Dr. Craig
Mello, RXI-109, an sd-rxRNA compound, is the Company's first
clinical development candidate. RXI-109 silences Connective Tissue
Growth Factor (CTGF), which plays a key role in tissue regeneration
and repair and is initially being developed to reduce or inhibit
scar formation in the skin and in the eye. RXI-109 is currently
being evaluated in Phase 2a clinical trials in dermatology and a
Phase 1/2 trial is planned to initiate this year in ophthalmology.
The Company's sd-rxRNA technology platform is broadly protected by
multiple issued patents and numerous patent applications.
RXi's robust pipeline, coupled with an extensive patent
portfolio, provides for product and business development
opportunities across a broad spectrum of therapeutic areas. We are
committed to being a partner of choice for academia, small
companies, and large multinationals. We welcome ideas and proposals
for strategic alliances, including in- and out-licensing
opportunities, to advance and further develop strategic areas of
interest. Additional information may be found on the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-premier-scientific-plastic-surgery-meeting-300157567.html
SOURCE RXi Pharmaceuticals Corporation